PharmaVoice
AUGUST 10, 2022
Miruna Sasu is on a mission to use real world data to help wipe out cancer. She believes this audacious goal is within reach, and as president and CEO of COTA, she is inspiring her team to create a “path to care” for oncology patients.
pharmaphorum
AUGUST 12, 2022
Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. That’s the position of multiple patient organisations, clinicians and medical groups, who have criticised the Department of Health’s decision to defer procurement of Evusheld supplies until cost-effectiveness agency
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
AUGUST 12, 2022
In June this year, it was announced that the US Food and Drug Administration (FDA) had granted UK-based OxfordVR a breakthrough device designation for its gameChangeVR treatment to deliver immersive cognitive behaviour therapy (CBT) to people suffering from schizophrenia and other mental illnesses. The FDA’s breakthrough device programme is for medical devices or device-led combination products that provide more effective treatment or diagnosis of diseases.
PharmExec
AUGUST 10, 2022
The technology is not just about digital enablement anymore.
Speaker: Jennifer Hill
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
PharmaVoice
AUGUST 9, 2022
[link]
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Times
AUGUST 11, 2022
University of Aberdeen team suggest results indicate that protein PAI-1 could be an early indicator of severe COVID-19
PharmExec
AUGUST 10, 2022
Failed efforts do not overshadow field’s progress, resolve.
PharmaVoice
AUGUST 11, 2022
What top executives at Merck, Pfizer and more are saying about M&A as they move into the second half of the year.
Pharmacy Is Right For Me
AUGUST 10, 2022
There are so many different types of careers within the field of pharmacy—from research and drug development to pharmacy informatics! To highlight some of the more unique career settings in the industry, we’re introducing a new page on our website— Novel Pharmacy Practice Settings —where you can explore these unique career pathways. In addition to learning more about unique pathways on our new webpage, we’ll also be featuring pharmacists who work in these unique settings on our blog.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharma Times
AUGUST 10, 2022
Newly diagnosed patients will become the first to access systemic light chain amyloidosis treatment in the UK
The Thyroid Pharmacist
AUGUST 12, 2022
Did you know that most cases of thyroid disease are autoimmune in nature? (1). Hashimoto’s thyroiditis is an autoimmune condition that happens to affect the thyroid gland. This means that our immune system recognizes the thyroid gland as a foreign invader and begins to attack it, eventually leading to the destruction of our thyroid tissue. When this destruction goes on long enough, the person will lose their ability to produce thyroid hormone.
PharmaVoice
AUGUST 9, 2022
With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.
PharmExec
AUGUST 10, 2022
Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?
Advertisement
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
Pharma Times
AUGUST 12, 2022
Radioligand therapy involves patients with advanced prostate cancer in Great Britain
Pharmaceutical Technology
AUGUST 10, 2022
The US Food and Drug Administration (FDA) has granted Fast-Track designation to Relmada Therapeutics’ REL-1017 as a single agent to treat major depressive disorder (MDD). A new chemical entity and NMDA receptor (NMDAR) channel blocker, REL-1017 acts on hyperactive channels while preserving physiological glutamatergic neurotransmission. Presently, the therapy is being analysed in late-stage studies.
PharmaVoice
AUGUST 8, 2022
While compensation packages at the top may not always reflect value, it’s not necessarily an industry-wide problem.
PharmExec
AUGUST 10, 2022
Marie-France Tschudin, president, innovative medicines international, and chief commercial officer at Novartis, taps into life lessons to help bring therapies to people in novel ways.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
AUGUST 11, 2022
Partnership will focus on driving the application of microscopy in drug discovery
Pharmaceutical Commerce
AUGUST 11, 2022
Pharmaceutical distribution today is anything but monolithic. While companies in this space are grappling with issues ranging from inflation and supply chain disruption to workforce scarcity and DSCSA implementation, there’s still plenty of room for smaller players to stake out part of the terrain to call their own.
PharmaVoice
AUGUST 11, 2022
Galderma may not have the biggest name in aesthetics, but as the sector grows past pandemic lows, the company is relying on its people to build a loyal customer base.
European Pharmaceutical Review
AUGUST 11, 2022
The Frost & Sullivan Institute stated that it is proud to present Samsung Biologics with the 2022 Enlightened Growth Leadership Award for not only demonstrating growth excellence but also social responsibility. In announcing the award, the Institute asserted that it “believes that all organisations must either create or become part of a solution that addresses threats to humanity,” highlighting Samsung’s strong environmental, social and governance (ESG) and sustainability initiatives the rea
Speaker: Joe Sharpe and James Carlson
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
Pharma Times
AUGUST 8, 2022
Study involved patients with locally advanced, unresectable stage 3 non-small cell lung cancer
pharmaphorum
AUGUST 8, 2022
Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing.
PharmaVoice
AUGUST 10, 2022
A consultant’s view on how pharma companies should approach patient experience challenges when rolling out an autologous cell therapy.
Pharmaceutical Technology
AUGUST 12, 2022
The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults. The treatment is indicated for such patients whose tumours have activating HER2 (ERBB2) mutations and previously received systemic therapy. .
Advertisement
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Expert insights. Personalized for you.
290 
Let's personalize your content